CARDIOLOGY / CLINICAL RESEARCH
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
In Mexico, cardiovascular diseases (CVD) represent the most important cause of mortality, disability, and premature death. We aimed to analyze the mortality rate due to specific causes of atherothrombotic CVD, from 2011 to 2015.

Material and methods:
We analyzed 3,105,975 death certificates issued between January 2011 and December 2015. The 10th version of the codes published by the International Classification of Diseases (ICD) was used to select CVD death records for ischemic heart disease, heart failure, cerebrovascular disease, and peripheral artery disease. Regional analyses from the different federal states were also performed to provide inferences on the economic regions of the country.

Results:
We analyzed 594,370 (19.1%) death certificates with CVD as the basic cause of death occurring in Mexico during 2011–2015. Age-standardized CVD mortality showed a more stable pattern, from 96.7 per 100,000 people in 2011, to 111.7 per 100,000 in 2015. Cause-specific mortality rates increased more during the period for ischemic heart disease (63.8 vs. 74.8 per 100,000 people, in 2011 vs. 2015, respectively), as compared to heart failure (6.9 vs. 8.1 per 100,000 people), cerebrovascular disease (28.4 vs. 30.2 per 100,000 people), or peripheral artery disease (0.52 vs. 0.55 per 100,000 people). Overall, the survival age was significantly shorter in men (mean age at death 72.04 ±16.23 years) than in women (77.73 ±14.77). Ischemic heart disease and cerebrovascular disease showed the shortest survival. The number of deaths increased steadily among the older population, with the steepest increase for overall ischemic heart disease over time.

Conclusions:
Atherothrombotic CVD mortality in Mexico increased during the study period, particularly at the expense of ischemic heart disease. Compared to their counterparts, survival age was shorter in men and in patients with ischemic heart disease and stroke.
REFERENCES (26)
1.
Rodríguez-Reyes H, Lara-Vaca S, Ochoa-Guzmán A, Chiquete E; ReMeFa Study Group. Obesity paradox and 12-month outcome in patients with atrial fibrillation. Arch Med Res 2021; 52: 233-9.
 
2.
Mazidi M, Katsiki N, Mikhailidis DP, Pella D, Banach M. Potato consumption is associated with total and cause-specific mortality: a population-based cohort study and pooling of prospective studies with 98,569 participants. Arch Med Sci 2020; 16: 260-72.
 
3.
Benjamin E, Blaha M, Chiuve S, et al. Heart disease and stroke statistics-207 update: a report from the American Heart Association. Circulation 2017; 135: 146-603.
 
4.
Walicka M, Puzianowska-Kuznicka M, Chlebus M, et al. Relationship between age and in-hospital mortality during 15,345,025 non-surgical hospitalizations. Arch Med Sci 2021; 17: 40-6.
 
5.
Chiquete E, Sandoval-Rodríguez V, García-Grimshaw M, et al. Reliability of bystander recognition of clinical features in pre-hospital classification of acute cerebrovascular syndromes: preliminary findings. Rev Invest Clin 2020; 73. DOI: 10.24875/RIC.20000238.
 
6.
Rosas-Peralta M, Arizmendi-Uribe E, Borrayo-Sánchez G. [What do adults die in Mexico? Impact on the economic and social development of the nation. The global burden of cardiovascular disease]. Rev Med Inst Mex Seguro Soc 2017; 55: 98-103.
 
7.
Morales L, Flores Y, Leng M, et al. Risk factors for cardiovascular disease among Mexican-American adults in the United States and Mexico: a comparative study. Salud Publica Mex 2014; 56: 197-205.
 
8.
Rosas M, Borrayo G, Ramírez E, et al. Cardiovascular risk reduction: past, present and future in México. Ann Clin Hypertens 2018; 2: 038-047.
 
9.
General mortality databases, Mexico. Accessed July 20, 2020. (http://www.dgis.salud.gob.mx/c...).
 
10.
Censo de Población y Vivienda 2010. INEGI. Disponible en: https://www.inegi.org.mx/progr....
 
11.
Quezada AD, Lozada-Tequeanes AL. Time trends and sex differences in associations between socioeconomic status indicators and overweight-obesity in Mexico (2006-2012). BMC Public Health 2015; 15: 1244.
 
12.
Gutierrez JP, Agudelo-Botero M, Garcia-Saiso S, et al. Advances and challenges on the path toward the SDGs: subnational inequalities in Mexico, 1990-2017. BMJ Glob Health 2020; 5: e002382.
 
13.
Barquera S, Pedroza-Tobías A, Medina C, et al. Global overview of the epidemiology of atherosclerotic cardiovascular disease. Arch Med Res 2015; 46: 328-38.
 
14.
Patsourakos NG, Kouvari M, Kotidis A, et al. The incidence of recurrent cardiovascular events among acute coronary syndrome patients treated with generic or original clopidogrel in relation to their sociodemographic and clinical characteristics. The Aegean study. Arch Med Sci 2020; 16: 1013-21.
 
15.
Mazidi M, Shekoohi N, Katsiki N, Banach M. Omega-6 fatty acids and the risk of cardiovascular disease: insights from a systematic review and meta-analysis of randomized controlled trials and a Mendelian randomization study. Arch Med Sci 2021; 18: 466-79.
 
16.
Alegre J, Herrington W, Lopez M, et al. Diabetes and cause-specific mortality in Mexico City. N Engl J Med 2016; 375: 1961-71.
 
17.
Einarson T, Acs A, Ludwig C, et al. The economic burden of cardiovascular disease in type 2 diabetes: a systematic review. Value Health 2018; 21: 881-90.
 
18.
Ramphul K, Ramphul Y, Sombans S, et al. Incidence and mortality rates of acute ischemic stroke in hospitalized patients in the United States. Arch Med Sci Atheroscler Dis 2021; 6: e132-4.
 
19.
AHA Statistical Update. Heart Disease and Stroke Statistics – 2018 Update. Circulation 2018; 137: 67-492.
 
20.
Maragkoudakis S, Marketou M, Katsi V, et al. The early effect of dapagliflozin on strain and tissue Doppler parameters of diastolic function in diabetic patients with heart failure with reduced ejection fraction. Arch Med Sci Atheroscler Dis 2021; 6: e176-81.
 
21.
Vintimilla R, Reyes M, Johnson L, Hall J, O’Bryant S. Cardiovascular risk factors in Mexico and the United States: a comparative cross-sectional study between the HABLE and MHAS participants. Gac Med Mex 2020; 156: 17-21.
 
22.
Malta DC, Teixeira R, Oliveira GMM, Ribeiro ALP. Cardiovascular disease mortality according to the brazilian information system on mortality and the Global Burden of Disease Study estimates in Brazil, 2000-2017. Arq Bras Cardiol 2020; 115: 152-60.
 
23.
Rubinstein A, Colantonio L, Bardach A, et al. Estimation of the burden of cardiovascular disease attributable to modifiable risk factors and cost-effectiveness analysis of preventative interventions to reduce this burden in Argentina. BMC Public Health 2010; 10: 627.
 
24.
Orzechowski P, Piotrowicz R, Zareba W, et al. Antiarrhythmic effect of 9-week hybrid comprehensive telerehabilitation and its influence on cardiovascular mortality in long-term follow-up – subanalysis of the TELEREHabilitation in Heart Failure Patients randomized clinical trial. Arch Med Sci 2021; 18: 293-306.
 
25.
Alswat K. Type 2 diabetes control and complications and their relation to serum magnesium level. Arch Med Sci 2021; 18: 307-13.
 
26.
Arroyo-Quiroz C, Barrientos-Gutierrez T, et al. Coronary heart disease mortality is decreasing in Argentina, and Colombia, but keeps increasing in Mexico: a time trend study. BMC Public Health 2020; 20: 162.
 
eISSN:1896-9151
ISSN:1734-1922
Journals System - logo
Scroll to top